Background: Ruxolitinib, a novel inhibitor of Janus kinases 1 and 2, was recently approved for the treatment of\nmyelofibrosis but, recently, attention has been drawn to potential side effects and especially opportunistic infections\nand virus reactivations. EBV reactivation has not previously been reported to occur in association with Ruxolitinib.\nCase presentation: We report a case of a 57 year old female with post-polycythemic myelofibrosis who was treated\nwith Ruxolitinib. Approximately 9 weeks later she presented with a rapidly fatal, suspected EBV driven lymphoproliferative\ndisorder in the CNS.\nConclusions: Our report further underlines that patients treated with Ruxolitinib should be monitored closely for\nreactivations of opportunistic pathogens and viral infections
Loading....